The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international internet-based survey of 1179 MPD patients

Ruben A. Mesa, Joyce Niblack, Martha Wadleigh, Srdan Verstovsek, John K Camoriano, Sunni Barnes, Angelina D. Tan, Pamela J. Atherton, Jeff A Sloan, Ayalew Tefferi

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

BACKGROUND. Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD). METHODS. The authors used validated instruments of fatigue and physical activity assessment during an Internet-based symptom survey of 1179 MPD patients (median age, 56 years; 41.4% men). RESULTS. The frequency of self-reporting was 80.7% for fatigue, which was substantially higher than that of pruritus (52.2%), night sweats (49.2%), bone pain (43.9%), fever (13.7%), and weight loss (13.1%). In the majority of patients, these symptoms restricted participation in both social functions and physical activity. In addition, 34.5% of patients needed assistance with activities of daily living, and 11.2% reported MPD-associated medical disability. As expected, the presence of myelofibrosis, anemia, splenomegaly, or other features associated with advanced disease favored a higher degree of fatigue. However, fatigue remained the major complaint also in polycythemia vera (84.9%) and essential thrombocythemia (72.4%); these figures were significantly higher than those of published controls (P < .0001). CONCLUSIONS. The current study identifies fatigue as the major contributor to poor quality of life in MPD, provides baseline information on constitutional symptoms, and underscores the need for the incorporation of quality of life assessment in clinical trials.

Original languageEnglish (US)
Pages (from-to)68-76
Number of pages9
JournalCancer
Volume109
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Myeloproliferative Disorders
Internet
Fatigue
Quality of Life
Exercise
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Sweat
Splenomegaly
Pruritus
Activities of Daily Living
Surveys and Questionnaires
Anemia
Weight Loss
Fever
Clinical Trials
Bone and Bones
Pain

Keywords

  • Constitutional symptoms
  • Fatigue
  • Myelofibrosis
  • Myeloproliferative disorders
  • Polycythemia vera
  • Quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) : An international internet-based survey of 1179 MPD patients. / Mesa, Ruben A.; Niblack, Joyce; Wadleigh, Martha; Verstovsek, Srdan; Camoriano, John K; Barnes, Sunni; Tan, Angelina D.; Atherton, Pamela J.; Sloan, Jeff A; Tefferi, Ayalew.

In: Cancer, Vol. 109, No. 1, 01.01.2007, p. 68-76.

Research output: Contribution to journalArticle

Mesa, Ruben A. ; Niblack, Joyce ; Wadleigh, Martha ; Verstovsek, Srdan ; Camoriano, John K ; Barnes, Sunni ; Tan, Angelina D. ; Atherton, Pamela J. ; Sloan, Jeff A ; Tefferi, Ayalew. / The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) : An international internet-based survey of 1179 MPD patients. In: Cancer. 2007 ; Vol. 109, No. 1. pp. 68-76.
@article{33cbb7d3bd794697aee5d91e5ec4cfc1,
title = "The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international internet-based survey of 1179 MPD patients",
abstract = "BACKGROUND. Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD). METHODS. The authors used validated instruments of fatigue and physical activity assessment during an Internet-based symptom survey of 1179 MPD patients (median age, 56 years; 41.4{\%} men). RESULTS. The frequency of self-reporting was 80.7{\%} for fatigue, which was substantially higher than that of pruritus (52.2{\%}), night sweats (49.2{\%}), bone pain (43.9{\%}), fever (13.7{\%}), and weight loss (13.1{\%}). In the majority of patients, these symptoms restricted participation in both social functions and physical activity. In addition, 34.5{\%} of patients needed assistance with activities of daily living, and 11.2{\%} reported MPD-associated medical disability. As expected, the presence of myelofibrosis, anemia, splenomegaly, or other features associated with advanced disease favored a higher degree of fatigue. However, fatigue remained the major complaint also in polycythemia vera (84.9{\%}) and essential thrombocythemia (72.4{\%}); these figures were significantly higher than those of published controls (P < .0001). CONCLUSIONS. The current study identifies fatigue as the major contributor to poor quality of life in MPD, provides baseline information on constitutional symptoms, and underscores the need for the incorporation of quality of life assessment in clinical trials.",
keywords = "Constitutional symptoms, Fatigue, Myelofibrosis, Myeloproliferative disorders, Polycythemia vera, Quality of life",
author = "Mesa, {Ruben A.} and Joyce Niblack and Martha Wadleigh and Srdan Verstovsek and Camoriano, {John K} and Sunni Barnes and Tan, {Angelina D.} and Atherton, {Pamela J.} and Sloan, {Jeff A} and Ayalew Tefferi",
year = "2007",
month = "1",
day = "1",
doi = "10.1002/cncr.22365",
language = "English (US)",
volume = "109",
pages = "68--76",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)

T2 - An international internet-based survey of 1179 MPD patients

AU - Mesa, Ruben A.

AU - Niblack, Joyce

AU - Wadleigh, Martha

AU - Verstovsek, Srdan

AU - Camoriano, John K

AU - Barnes, Sunni

AU - Tan, Angelina D.

AU - Atherton, Pamela J.

AU - Sloan, Jeff A

AU - Tefferi, Ayalew

PY - 2007/1/1

Y1 - 2007/1/1

N2 - BACKGROUND. Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD). METHODS. The authors used validated instruments of fatigue and physical activity assessment during an Internet-based symptom survey of 1179 MPD patients (median age, 56 years; 41.4% men). RESULTS. The frequency of self-reporting was 80.7% for fatigue, which was substantially higher than that of pruritus (52.2%), night sweats (49.2%), bone pain (43.9%), fever (13.7%), and weight loss (13.1%). In the majority of patients, these symptoms restricted participation in both social functions and physical activity. In addition, 34.5% of patients needed assistance with activities of daily living, and 11.2% reported MPD-associated medical disability. As expected, the presence of myelofibrosis, anemia, splenomegaly, or other features associated with advanced disease favored a higher degree of fatigue. However, fatigue remained the major complaint also in polycythemia vera (84.9%) and essential thrombocythemia (72.4%); these figures were significantly higher than those of published controls (P < .0001). CONCLUSIONS. The current study identifies fatigue as the major contributor to poor quality of life in MPD, provides baseline information on constitutional symptoms, and underscores the need for the incorporation of quality of life assessment in clinical trials.

AB - BACKGROUND. Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD). METHODS. The authors used validated instruments of fatigue and physical activity assessment during an Internet-based symptom survey of 1179 MPD patients (median age, 56 years; 41.4% men). RESULTS. The frequency of self-reporting was 80.7% for fatigue, which was substantially higher than that of pruritus (52.2%), night sweats (49.2%), bone pain (43.9%), fever (13.7%), and weight loss (13.1%). In the majority of patients, these symptoms restricted participation in both social functions and physical activity. In addition, 34.5% of patients needed assistance with activities of daily living, and 11.2% reported MPD-associated medical disability. As expected, the presence of myelofibrosis, anemia, splenomegaly, or other features associated with advanced disease favored a higher degree of fatigue. However, fatigue remained the major complaint also in polycythemia vera (84.9%) and essential thrombocythemia (72.4%); these figures were significantly higher than those of published controls (P < .0001). CONCLUSIONS. The current study identifies fatigue as the major contributor to poor quality of life in MPD, provides baseline information on constitutional symptoms, and underscores the need for the incorporation of quality of life assessment in clinical trials.

KW - Constitutional symptoms

KW - Fatigue

KW - Myelofibrosis

KW - Myeloproliferative disorders

KW - Polycythemia vera

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=33846266634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846266634&partnerID=8YFLogxK

U2 - 10.1002/cncr.22365

DO - 10.1002/cncr.22365

M3 - Article

C2 - 17123268

AN - SCOPUS:33846266634

VL - 109

SP - 68

EP - 76

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -